Evidence map›Paper›PMID 41015178›Full record

ArticleJournal of advanced research2026

Analyzing and forecasting global cervical cancer burden based on WHO's elimination strategy: insights and projections from a 1990-2021 global burden of disease (GBD) study covering 204 countries and territories.

Yedong Huang, Wenyu Lin, Xiaoyun Chen, Xiangqin Zheng, Huan Yi, Lin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yedong HuangFujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; National Key Gynecology Clinical Specialty Construction Institution of China, Fujian Provincial Key Gynecology Clinical Specialty, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Wenyu LinFujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; Medical Genetic Diagnosis and Therapy Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, Fuzhou, China.
Xiaoyun ChenThe School of Clinical Medicine, Fujian Medical University, Department of Respiratory and Critical Care Medicine, Fujian Provincial Geriatric Hospital, Fuzhou, China.
Xiangqin ZhengFujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; National Key Gynecology Clinical Specialty Construction Institution of China, Fujian Provincial Key Gynecology Clinical Specialty, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China. Electronic address: zhengxq1118@126.com.
Huan YiFujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; National Key Gynecology Clinical Specialty Construction Institution of China, Fujian Provincial Key Gynecology Clinical Specialty, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China. Electronic address: huan.yi@med.lu.se.
Lin ZhangFujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; Department of Epidemiology and Preventive Medicine, The School of Public Health and Preventive Medicine, Monash University, Australia; Suzhou Industrial Park Monash Research Institute of Science and Technology, Monash University, China. Electronic address: lin.zhang2@monash.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCervical cancer remains a major global public health challenge. In 2018, the WHO launched a strategy to eliminate cervical cancer, emphasizing the need for precise epidemiological assessments.

objectivesThis study utilized Global Burden of Disease (GBD) data to analyze the epidemiological indicators, geographical patterns, and temporal trends of cervical cancer, evaluating the global impact of the WHO's strategy.

methodsData on cervical cancer from 204 countries and territories (from 1990 to 2021) were retrieved from the GBD database. The year 2018, marking the WHO's global call for elimination, was used to divide data into two periods: 1990 to 2018 and 2019 to 2021. Trends in age-standardized incidence rates and disability-adjusted life years (DALYs) were assessed using estimated annual percentage changes (EAPCs) and joinpoint regression. The socio-demographic index (SDI) was regressed against epidemiological indicators to explore disparities. Health inequality analyses recommended by the WHO were conducted, and an autoregressive integrated moving average (ARIMA) model was applied to predict future trends.

resultsFrom 1990 to 2021, global age-standardized incidence rates and DALYs declined. During 1990 to 2018, the highest EAPC values were observed in Southern Sub-Saharan Africa (2·18), East Asia (0·69), and Eastern Europe (0·31). After 2019, a more significant improvement was noted globally. Regression analyses revealed an SDI-related gradient, with low-SDI countries lagging. Health inequality analyses showed widening disparities. ARIMA projections indicated stable incidence rates in most regions but a continued decline in DALYs.

conclusionThe WHO's strategy has contributed to a notable decline in cervical cancer burden, yet challenges persist in low-SDI regions. Strengthening global cooperation and resource allocation is essential for achieving elimination goals.

Indexed as

Global Burden of DiseaseUterine Cervical NeoplasmsDisability-Adjusted Life YearsFemaleForecastingGlobal HealthHumansIncidenceQuality-Adjusted Life YearsWorld Health OrganizationCervical CancerEpidemiologyForecastGlobal Burden of Disease (GBD)World Health Organization (WHO)

Identifiers

PMID41015178
PMCPMC13227222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.